Compare Stocks: ADMA, ACAD, ALLO, and APGE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$29.50 +1.6%	$25.96	$19.69 ▼ $30.96	$5.08B	0.81	1.80 million shs	1.09 million shs
ADMA ADMA Biologics	$9.84 +0.8%	$8.96	$7.21 ▼ $20.46	$2.20B	0.74	2.43 million shs	1.48 million shs
ALLO Allogene Therapeutics	$2.09 -0.5%	$1.98	$1.04 ▼ $4.46	$722.08M	0.48	6.02 million shs	4.37 million shs
APGE Apogee Therapeutics	$134.75	$129.31	$35.39 ▼ $134.88	$8.38B	0.34	1.26 million shs	948,283 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+4.46%	+18.81%	+39.81%	+18.28%
ADMA ADMA Biologics	0.00%	+3.91%	+17.56%	+19.42%	-43.12%
ALLO Allogene Therapeutics	0.00%	+1.95%	+14.84%	+4.50%	+97.17%
APGE Apogee Therapeutics	0.00%	+0.15%	+0.36%	+66.03%	+274.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$29.50 +1.6%	$25.96	$19.69 ▼ $30.96	$5.08B	0.81	1.80 million shs	1.09 million shs
ADMA ADMA Biologics	$9.84 +0.8%	$8.96	$7.21 ▼ $20.46	$2.20B	0.74	2.43 million shs	1.48 million shs
ALLO Allogene Therapeutics	$2.09 -0.5%	$1.98	$1.04 ▼ $4.46	$722.08M	0.48	6.02 million shs	4.37 million shs
APGE Apogee Therapeutics	$134.75	$129.31	$35.39 ▼ $134.88	$8.38B	0.34	1.26 million shs	948,283 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+4.46%	+18.81%	+39.81%	+18.28%
ADMA ADMA Biologics	0.00%	+3.91%	+17.56%	+19.42%	-43.12%
ALLO Allogene Therapeutics	0.00%	+1.95%	+14.84%	+4.50%	+97.17%
APGE Apogee Therapeutics	0.00%	+0.15%	+0.36%	+66.03%	+274.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.82	Moderate Buy	$34.19	15.91% Upside
ADMA ADMA Biologics	2.33	Hold	$18.67	89.70% Upside
ALLO Allogene Therapeutics	2.69	Moderate Buy	$8.30	297.13% Upside
APGE Apogee Therapeutics	2.20	Hold	$124.43	-7.66% Downside

Current Analyst Ratings Breakdown

Latest ADMA, ACAD, ALLO, and APGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $49.00
8/17/2026	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$6.00
8/13/2026	APGE Apogee Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$81.00 ➝ $135.00
8/12/2026	ACAD ACADIA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/12/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/12/2026	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $41.00
8/12/2026	APGE Apogee Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/10/2026	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$27.00
8/10/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$35.00 ➝ $39.00
8/6/2026	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $37.00

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.07B	4.74	$0.89 per share	33.25	$7.58 per share	3.89
ADMA ADMA Biologics	$512.28M	4.30	$0.65 per share	15.04	$1.82 per share	5.41
ALLO Allogene Therapeutics	$20K	36,103.71	N/A	N/A	$1.26 per share	1.66
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$19.21 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.22	13.29	31.05	23.23	33.42%	9.03%	6.79%	11/4/2026 (Estimated)
ADMA ADMA Biologics	$146.93M	$0.70	14.06	11.58	N/A	32.98%	40.17%	26.97%	11/4/2026 (Estimated)
ALLO Allogene Therapeutics	-$190.89M	-$0.67	N/A	N/A	N/A	N/A	-50.04%	-36.74%	11/5/2026 (Estimated)
APGE Apogee Therapeutics	-$255.84M	-$4.34	N/A	N/A	N/A	N/A	-29.88%	-28.08%	11/9/2026 (Estimated)

Latest ADMA, ACAD, ALLO, and APGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ALLO Allogene Therapeutics	-$0.1714	-$0.13	+$0.0414	-$0.13	$0.00 million	$4.64 million
8/10/2026	Q2 2026	APGE Apogee Therapeutics	-$1.07	-$1.14	-$0.07	-$1.14	$10.00 million	N/A
8/5/2026	Q2 2026	ADMA ADMA Biologics	$0.1633	$0.16	-$0.0033	$0.16	$125.34 million	$124.40 million
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0682	$0.18	+$0.1119	$0.18	$296.55 million	$308.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.39	3.30
ADMA ADMA Biologics	0.49	6.97	3.81
ALLO Allogene Therapeutics	N/A	10.72	10.72
APGE Apogee Therapeutics	N/A	26.44	26.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
ADMA ADMA Biologics	75.68%
ALLO Allogene Therapeutics	83.63%
APGE Apogee Therapeutics	79.04%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
ADMA ADMA Biologics	3.90%
ALLO Allogene Therapeutics	13.20%
APGE Apogee Therapeutics	24.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	172.31 million	127.16 million	Optionable
ADMA ADMA Biologics	530	223.99 million	215.25 million	Optionable
ALLO Allogene Therapeutics	310	345.49 million	299.89 million	Optionable
APGE Apogee Therapeutics	91	62.20 million	47.09 million	Optionable

ADMA, ACAD, ALLO, and APGE Headlines

Recent News About These Companies

Deutsche Bank AG Acquires New Stake in Apogee Therapeutics Inc. $APGE

August 23 at 3:36 AM | marketbeat.com

BlackRock Inc. Takes $730.95 Million Position in Apogee Therapeutics Inc. $APGE

August 23 at 3:28 AM | marketbeat.com

Apogee Therapeutics (NASDAQ:APGE) Hits New 1-Year High - Should You Buy?

August 19, 2026 | marketbeat.com

NINE MASTS CAPITAL Ltd Takes Position in Apogee Therapeutics Inc. $APGE

August 18, 2026 | marketbeat.com

Alberta Investment Management Corp Purchases New Position in Apogee Therapeutics Inc. $APGE

August 17, 2026 | marketbeat.com

Apogee Therapeutics Inc. (NASDAQ:APGE) Given Average Recommendation of "Hold" by Analysts

August 15, 2026 | americanbankingnews.com

Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Consensus Recommendation of "Hold" from Analysts

August 15, 2026 | marketbeat.com

Handelsbanken Fonder AB Has $11.46 Million Stake in Apogee Therapeutics Inc. $APGE

August 14, 2026 | marketbeat.com

BTIG Research Downgrades Apogee Therapeutics (NASDAQ:APGE) to Neutral

August 14, 2026 | americanbankingnews.com

This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

August 12, 2026 | benzinga.com

Apogee Therapeutics (NASDAQ:APGE) Stock Rating Lowered by BTIG Research

August 12, 2026 | marketbeat.com

Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

August 10, 2026 | finanznachrichten.de

Apogee Therapeutics (NASDAQ:APGE) Issues Earnings Results, Misses Expectations By $1.00 EPS

August 10, 2026 | marketbeat.com

Apogee Therapeutics Inc. $APGE Shares Acquired by Bank of America Corp DE

August 10, 2026 | marketbeat.com

Carl Dambkowski Sells 5,500 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock

August 8, 2026 | insidertrades.com

Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 5,500 Shares

August 7, 2026 | marketbeat.com

Sei Investments Co. Grows Stock Holdings in Apogee Therapeutics Inc. $APGE

August 7, 2026 | marketbeat.com

Apogee Therapeutics (NASDAQ:APGE) Sets New 52-Week High - What's Next?

August 6, 2026 | marketbeat.com

Apogee Therapeutics Inc. $APGE Shares Sold by The Manufacturers Life Insurance Company

August 6, 2026 | marketbeat.com

First Trust Advisors LP Grows Stock Holdings in Apogee Therapeutics Inc. $APGE

August 6, 2026 | marketbeat.com

Is Apogee Therapeutics (APGE) Fully Priced, Or Still A Bargain?

August 3, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ADMA, ACAD, ALLO, and APGE Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$29.50 +0.46 (+1.58%)

As of 08/21/2026 04:00 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ADMA Biologics NASDAQ:ADMA

$9.84 +0.08 (+0.82%)

As of 08/21/2026 04:00 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Allogene Therapeutics NASDAQ:ALLO

$2.09 -0.01 (-0.48%)

As of 08/21/2026 04:00 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Apogee Therapeutics NASDAQ:APGE

$134.75 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADMA, ACAD, ALLO, and APGE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADMA, ACAD, ALLO, and APGE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADMA, ACAD, ALLO, and APGE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ADMA, ACAD, ALLO, and APGE Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

ADMA Biologics NASDAQ:ADMA

Allogene Therapeutics NASDAQ:ALLO

Apogee Therapeutics NASDAQ:APGE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADMA, ACAD, ALLO, and APGE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADMA, ACAD, ALLO, and APGE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADMA, ACAD, ALLO, and APGE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ADMA, ACAD, ALLO, and APGE Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

ADMA Biologics NASDAQ:ADMA

Allogene Therapeutics NASDAQ:ALLO

Apogee Therapeutics NASDAQ:APGE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools